Literature DB >> 9522039

Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat.

K Müller1, I Wiesenberg, K Jaeggi, J R Green.   

Abstract

The effect of the bisphosphonate zoledronate (CAS 118072-93-8, CGP 42446) on trabecular bone in two rat models of osteopenia, i.e. the ovariectomized rat and the adjuvant arthritic rat, was tested and compared to the activity of alendronate and pamidronate. All three bisphosphonates prevented bone loss in the distal femur and in the lumbar vertebrae in both animal models, as measured by chemical analysis and/or bone densitometry. Zoledronate was the most potent bisphosphonate, 10-30 times more potent than alendronate and 120 times more potent than pamidronate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9522039

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

Review 2.  The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.

Authors:  P Hadji; R Coleman; M Gnant; J Green
Journal:  Ann Oncol       Date:  2012-06-22       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.